https://www.selleckchem.com/pr....oducts/etanercept.ht
Clinical Trials Registration ClinicalTrial.gov NCT04210271. The high prevalence of relapse in pediatric B-lineage acute lymphoblastic leukemia (B-ALL) despite the improvements achieved using current risk stratification schemes, demands more accurate methods for outcome prediction. Here, we provide a concise overview about the key advances that have expanded our knowledge regarding the somatic defects across B-ALL genomes, particularly focusing on copy number alterations (CNAs) and their prognostic impact. The identification of common
Like
Comment
Share
